UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 29, 2012 |
| |
HUBEI MINKANG PHARMACEUTICAL LTD.
(Exact name of registrant as specified in its charter) |
| |
Nevada
(State or other jurisdiction
of incorporation | 000-53231
(Commission
File Number) | 26-2410685
(IRS Employer
Identification No.) |
55 Ubi Ave. 3, #03-01, Mintwell Building
Singapore
(Address of principal executive offices) | 408864
(Zip Code) |
Registrant's telephone number, including area code +65-6747-7883 |
|
N/A
(Former name or former address, if changed since last report) |
| | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CRF 240.13e-4(c))
SECTION 8 - OTHER EVENTS
Item 8.01 Other Events
On February 29, 2012, we issued a press release with respect our Chinese subsidiary, Hubei Minkang Pharmaceutical Co., Ltd., entering into a Memorandum of Understanding with Henan Wanlong Pharmaceutical Co., Ltd. ("Henan Wanlong"), a Chinese company, with respect to a proposal for our subsidiary to acquire 51% of Henan Wanlong to expand distribution and increase sales growth.
A copy of the press release is attached as Exhibit 99.1 hereto.
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Shell Company Transactions.
Not applicable.
(d) Exhibits.
Exhibit No. | Description of Exhibit |
99.1 | Press release dated February 29, 2012. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 8, 2012
Hubei Minkang Pharmaceutical Ltd. |
| |
By: | | /S/ Lee Tong Tai |
Name: | | Lee Tong Tai |
Title: | | President and Director |
